The Total Synthesis of Pleurotin
The Total Synthesis of Pleurotin
批准号:
9467893
负责人:
Andrew Musacchio
金额:
$5.67万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-11 至 2019-09-10
关键词:
AntibioticsBindingBiologicalBiological AssayBiological TestingBiologyBreast Cancer CellCancer BiologyCarbonChemical StructureCollaborationsColon CarcinomaCyclizationCyclohexanesDevelopmentHT29 CellsHandHumanHypoxiaInvestigationIsotopesMCF7 cellMalignant Epithelial CellMalignant NeoplasmsNatural ProductsOxidation-ReductionPathway interactionsPleurotusPolyenesPrevalencePropertyProteolysisQuinonesReactionReportingResearchResearch ProposalsRouteSourceStructureSystemTestingVascular Endothelial Growth Factorsactivity-based protein profilinganalogangiogenesisantitumor agentbasecancer cellcancer therapycancer typechemical synthesisdecalindriving forceeffective therapyfight againsthypoxia inducible factor 1insightmigrationnovelnovel therapeuticspleuromutilinpleurotinscaffoldsmall molecule inhibitorthioredoxin reductasetranscription factortumortumor progression
中文摘要
项目摘要
通过以下途径选择性靶向癌细胞的新型癌症治疗方法的开发
癌症生物学特有的机制仍然是抗癌斗争中的一个重要挑战。
由于有大量不同的癌症类型,每种癌症都有其各自的特点,这项任务变得更加困难
拥有独特的生物学特性。然而,某些生物途径在许多不同的品种中是共同的
癌症,为开发癌症治疗的一般疗法提供了机会。一
这种途径就是低氧诱导的血管生成,它被认为是驱动力
对于大约70%的人类癌症类型。选择性小分子抗氧化剂的研究进展
途径将代表着癌症治疗向前迈出的重要一步,使有效治疗
各种不同的癌症类型。
侧耳素是一种抗生素真菌代谢物,于1947年首次分离,并被发现具有
强大的抗癌性能。尽管人们已经知道70年了,但它的确切机制
尽管已提出通过抑制来发挥作用,但侧柏木素的抗癌作用尚不清楚
低氧诱导的血管生成。这种被提出的生物学作用模式使胸苷成为一种
生物研究和化学合成的高价值目标。这项研究建议
本文描述了一种通过快速合成具有挑战性的反式侧耳素的简短的化学合成方法。
在天然产品中发现的氢化吲哚基元。由于反式-氢吲哚结构的普遍存在
在各种天然产品中,这一策略应该能够合成丰富的分子。
具有各种各样的生物活性。研究计划还概述了合成和生物测试
新的胸苷类似物。模拟合成和生物检测的结合将允许
阐明柴胡素的抗癌作用机制,可能导致新的一般
癌症的治疗。总体而言,拟议的研究将允许快速合成一个
重要的天然产物,并提供了关于抑制一种
人类癌症的流行驱动力。
英文摘要
Project Summary
Development of novel cancer therapies that selectively target cancer cells through
mechanisms unique to cancer biology remains an important challenge in the fight against cancer.
This task is made even more difficult due to the vast number of different cancer types, each with its
own unique biology. However, certain biological pathways are common to many different varieties of
cancer, providing an opportunity for the development of a general therapy for cancer treatment. One
such pathway is hypoxia-induced angiogenesis, which has been suggested to be the driving force
for around 70% of human cancer types. Development of a selective small molecule inhibitor of this
pathway would represent a major step forward in cancer treatment, enabling effective treatment of a
diverse range of different cancer types.
Pleurotin is an antibiotic fungal metabolite first isolated in 1947 and found to possess
powerful anticancer properties. Despite being known for 70 years, the exact mechanism of
pleurotin’s anticancer effect remains unknown, although it is proposed to function through inhibition
of hypoxia-induced angiogenesis. This proposed biological mode of action has made pleurotin a
high value target for both biological studies and chemical synthesis. This research proposal
describes a short chemical synthesis of pleurotin through rapid formation of the challenging trans-
hydrindane motif found in the natural product. Due to the prevalence of trans-hydrindane structures
in a variety of natural products, this strategy should enable the synthesis of a wealth of molecules
with varied biological activity. The research plan also outlines the synthesis and biological testing of
novel pleurotin analogs. The combination of analog synthesis and biological assays will allow for the
elucidation of the mechanism of pleurotin’s anticancer properties, potentially leading to new general
treatments for cancer. Overall, the proposed research will allow for the rapid synthesis of an
important natural product and provide valuable information on the mechanism of inhibition of a
prevalent driving force in human cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: